TP53 and melanoma: Although the levels of phospho JNK T183/Y185 were induced within 30 min of PLX4032 treatment (Figure S2C), there were no changes in the activated status of several known downstream JNK targets, such as p53, JUN and eIF4E in YUDOSO-BRAFWT melanoma cells, whereas only phospho-eIF4E Ser209 levels were reduced in YULAC-BRAFV600E cells (Figure S2D), suggesting very little functional consequences of JNK activation on BRAFWT melanoma cells.